JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

Начало・Списък с акции・Simulations Plus Inc

Simulations Plus Inc

Отворен

СекторЗдравеопазване

14.84 0.47

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.27

Максимум

14.94

Ключови измерители
By Trading Economics
Приходи	3.9M 4.5M
Продажби	5.9M 24M
EPS	0.35
Дивидентна доходност	0.48
Марж на печалбата	18.669
Служители	212
EBITDA	4.9M 7.2M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+9.89% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.48% 2.24%
Следващи печалби	13.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	51M 302M
Предишно отваряне	14.37
Предишно затваряне	14.84

Настроения в новините

By Acuity

21%

79%

52 / 348 Класиране в Healthcare

Simulations Plus Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27.04.2026 г., 23:08 ч. UTC

Печалби

Значими двигатели на пазара

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27.04.2026 г., 23:08 ч. UTC

Пазарно говорене

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27.04.2026 г., 22:42 ч. UTC

Пазарно говорене

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27.04.2026 г., 22:10 ч. UTC

Печалби

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27.04.2026 г., 21:56 ч. UTC

Печалби

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27.04.2026 г., 21:44 ч. UTC

Печалби

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27.04.2026 г., 21:43 ч. UTC

Печалби

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.04.2026 г., 20:39 ч. UTC

Печалби

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Сравнение с други в отрасъла

Ценова промяна

Simulations Plus Inc Прогноза

Ценова цел

By TipRanks

9.89% нагоре

12-месечна прогноза

Среден 16 USD 9.89%

Висок 16 USD

Нисък 16 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Simulations Plus Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Simulations Plus Inc през последните 3 месеца.

Настроение

By Acuity

52 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.